Mechanistic Modeling in Clinical Development


John M. Burke, PhD, Co-founder, President and CEO at Applied BioMath


In the final episode of this three-part GENcast series, we discuss the virtues of mechanistic modeling and how it can significantly impact critical decision-making points in the drug discovery process, an especially critical step as drug developers move closer to IND. Dr. John Burke, President, CEO, and Co-founder of Applied BioMath, discusses the specific applications of mechanistic modeling, including decision-making for first human dose numbers.

View our other podcasts in this GENcast Series

What is Mechanistic Modeling and How Can it be Applied in Drug Discovery?

Applying Mechanistic PK/PD Modeling Approaches in Preclinical Research